FDA Panel Will Bring A SHARP Eye To Vytorin, Zetia sNDAs For Chronic Kidney Disease
This article was originally published in The Pink Sheet Daily
Executive Summary
The agency's Endocrinologic and Metabolic Drugs Advisory Committee will meet on Nov. 2 to discuss whether the SHARP study results support use of the cholesterol-lowering agents for cardiovascular risk reduction in patients with renal disease.
You may also be interested in...
FDA Cmte. To Weigh Breadth Of Vytorin/Zetia CV Risk Reduction Claim In Renally Impaired Patients
The Endocrinologic and Metabolic Drugs Advisory Committee will vote Nov. 2 on whether a new claim for reducing the risk of major cardiovascular events based upon the SHARP study should apply to both the pre-dialysis and dialysis populations.
FDA Cmte. To Weigh Breadth Of Vytorin/Zetia CV Risk Reduction Claim In Renally Impaired Patients
The Endocrinologic and Metabolic Drugs Advisory Committee will vote Nov. 2 on whether a new claim for reducing the risk of major cardiovascular events based upon the SHARP study should apply to both the pre-dialysis and dialysis populations.
Merck Releases Positive Study For Vytorin, But How Much Impact Will It Have?
A positive outcome in the SHARP study is good news for Merck, but questions still remain about the efficacy of Vytorin compared to older statins.